Cue Health Receives Support from BARDA to Create Portable COVID Test for Omicron Population
April 6, 2023
Trending News ☀️
Cue Health ($NASDAQ:HLTH), an innovative health technology company, has recently received support from the Biomedical Advanced Research and Development Authority (BARDA) to develop a portable COVID test specific to the omicron strain. The company, which produces advanced mobile health technology solutions, is looking to improve the way physicians diagnose and treat diseases. Cue Health specializes in the development of remote patient monitoring systems, and the latest effort to create a portable COVID test is among its many advancements. Cue Health, with its unique and innovative approach to healthcare, has quickly become an industry leader in healthcare technology, earning recognition not only from BARDA but also from leading medical institutions and organizations.
The company’s mission is to make healthcare accessible, affordable, and efficient for everyone, and the upcoming portable COVID test for the omicron strain is just one example of how Cue Health is striving to do so. Cue Health’s collaboration with BARDA on this project is a testament to their commitment to providing quality health solutions for everyone.
Market Price
Following the news, the company’s stock opened at $1.8 and closed at $1.8, down by 2.8% from its prior closing price of 1.8. This was in spite of the generally positive sentiment in the market, indicating that investors were not convinced about the potential outcomes of the project. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cue Health. More…
| Total Revenues | Net Income | Net Margin |
| 474.17 | -194.06 | -40.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cue Health. More…
| Operations | Investing | Financing |
| -111.92 | -63.03 | -6.43 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cue Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 694.58 | 118.09 | 3.83 |
Key Ratios Snapshot
Some of the financial key ratios for Cue Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 315.2% | – | -42.8% |
| FCF Margin | ROE | ROA |
| -36.9% | -21.8% | -18.3% |
Analysis
At GoodWhale, we analyze CUE HEALTH‘s financials to gain insights into the company’s performance. After running our assessment, we found that according to Star Chart, CUE HEALTH is strong in asset, growth, and profitability, but weak in dividend. We give CUE HEALTH an intermediate health score of 6/10, considering its cashflows and debt. This score indicates that CUE HEALTH may be able to pay off debt and fund future operations. In addition, we classified CUE HEALTH as a ‘rhino’, a type of company with moderate revenue or earnings growth. Investors who are attracted to such companies may be interested in CUE HEALTH. Potential investors should take the time to understand CUE HEALTH’s financial performance in more detail before investing. More…
Peers
The healthcare industry is intensely competitive, with companies vying for market share in a variety of ways.
– Galileo Life Sciences Inc ($OTCPK:MDRM)
Galileo Life Sciences Inc is a publicly traded company with a market capitalization of 2.93M as of 2022. The company’s return on equity, a measure of profitability, is 199.87%. Galileo Life Sciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of cancer and other serious diseases. The company’s lead product candidate is a small molecule inhibitor of the PI3K/mTOR pathway, which is in clinical development for the treatment of advanced solid tumors.
– Privia Health Group Inc ($NASDAQ:PRVA)
Privately held Privia Health Group, Inc. is a national physician organization that partners with hospitals, health plans, and health systems to improve clinical and financial outcomes. The company provides a range of services, including population health management, care coordination, and revenue cycle management. Privia also offers a suite of technology solutions to help its partners deliver high-quality, cost-effective care.
– LifeStance Health Group Inc ($NASDAQ:LFST)
LifeStance Health Group Inc is a healthcare company with a focus on mental health and addiction. The company has a market cap of 2.92B as of 2022 and a Return on Equity of -14.92%. The company’s main offerings include outpatient mental health services, residential treatment facilities, and recovery support services. The company has been operational for over 20 years and has a presence in multiple states across the US.
Summary
Cue Health is a company developing a portable COVID test with the backing of the Biomedical Advanced Research and Development Authority (BARDA). Investment analysis of Cue Health involves evaluating the company’s ability to develop and market the omicron-specific COVID test, as well as its projected financial and operational performance. Investors may consider Cue Health’s competitive advantages over other companies in the industry when assessing its potential growth and profitability. Factors such as the company’s pricing strategy, partnerships, and product development timeline should also be taken into account.
Additionally, potential investors should evaluate the company’s management team and its ability to secure additional funding from investors or partners.
Related Posts
Recent Posts
